{"id":22482,"date":"2018-07-02T16:27:36","date_gmt":"2018-07-02T16:27:36","guid":{"rendered":"https:\/\/corporate.webfactory.ferring.tech\/?p=22482"},"modified":"2021-05-08T10:07:15","modified_gmt":"2021-05-08T09:07:15","slug":"new-analysis-of-rekovelle-data-further-supports-use-of-amh-to-personalise-fertility-treatment","status":"publish","type":"post","link":"https:\/\/www.ferring.com\/new-analysis-of-rekovelle-data-further-supports-use-of-amh-to-personalise-fertility-treatment\/","title":{"rendered":"New analysis of Rekovelle\u00ae data further supports use of AMH to personalise fertility treatment"},"content":{"rendered":"[spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;]\n<h2 style=\"color: #0088ce;\">New analysis of Rekovelle\u00ae data further supports use of AMH to personalise fertility treatment<\/h2>\n[\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;]\n<ul>\n<li>Rekovelle\u2019s unique dosing algorithm, which is based on a woman\u2019s anti-M\u00fcllerian hormone (AMH) level and body weight, is designed for predictable ovarian response<\/li>\n<\/ul>\n<ul>\n<li>New analysis shows that natural variations in a woman\u2019s AMH levels have no clinically relevant impact on ovarian response when using AMH to dose Rekovelle<\/li>\n<\/ul>\n<ul>\n<li>New analysis reinforces that AMH measured on any day of a woman\u2019s menstrual cycle can be used to determine her daily dose of Rekovelle<\/li>\n<\/ul>\n[\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;]\n<h3 style=\"color: #0088ce;\">Saint-Prex, Switzerland \u2013 2 July, 2018 \u2013<\/h3>\n<p>Ferring Pharmaceuticals announced today a new analysis* of data from the Phase 3 ESTHER-1 trial<span class=\"s2\"><sup><a href=\"#note1\">1<\/a><\/sup><\/span> showing that natural variations in anti-M\u00fcllerian hormone (AMH) levels during and between a woman\u2019s menstrual cycle have no clinically relevant impact on ovarian response (the number of eggs produced) when using AMH to dose Rekovelle\u00ae (follitropin delta) for ovarian stimulation (OS).<a href=\"#note2\"><span class=\"s2\"><sup>2<\/sup><\/span><\/a> The data were presented today at the 34th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in Barcelona, Spain.<\/p>\n<p>According to the new analysis, for 95% of women treated with Rekovelle, variations in ovarian response were limited to a difference of plus or minus one egg<a href=\"#note2\"><span class=\"s2\"><sup>2<\/sup><\/span><\/a>. This reinforces that AMH measured on any day of a woman\u2019s menstrual cycle can be used to individualise the dose of Rekovelle. AMH is measured with a companion diagnostic, the Elecsys\u00ae AMH Plus immunoassay from F. Hoffmann-La Roche Ltd (Roche).<\/p>\n<p>\u201cWe are excited to share the results of this new Rekovelle analysis which add to existing evidence showing AMH is a robust predictor of ovarian response to fertility treatment,\u201d said Professor Klaus Dugi, Chief Medical Officer, Ferring Pharmaceuticals. \u201cI believe these data will further strengthen the growing confidence of doctors in the use of AMH to personalise dosing of fertility treatment for their patients.\u201d<\/p>\n<p>Ovarian response to stimulation varies considerably from woman to woman<a href=\"#note3\"><span class=\"s2\"><sup>3<\/sup><\/span><\/a> and unexpected extreme responses have implications on efficacy and safety.<span class=\"s2\"><sup><a href=\"#note4\">4<\/a>,<a href=\"#note5\">5<\/a><\/sup><\/span> Aiming to avoid extremes in ovarian response, the validated Rekovelle dosing algorithm uses AMH and body weight to determine a personalised dose for patients, from the start of treatment.<\/p>\n<p>This analysis of data from the Phase 3 ESTHER-1 trial adds to consistent efficacy results seen with Rekovelle in clinical trials to date. The ESTHER-1 trial showed that women undergoing their first treatment cycle receiving individualised treatment with Rekovelle, compared to conventional dosing regimen with follitropin alfa,<span class=\"s2\"><sup><a href=\"#note1\">1<\/a>,\u2021\u00a7<\/sup><\/span> had similar ongoing pregnancy and embryo implantation rates.<span class=\"s2\"><sup><a href=\"#note1\">1<\/a><\/sup><\/span><\/p>\n<p>The ESTHER-1 trial also showed that more women receiving individualised treatment with Rekovelle achieved the target response of 8-14 eggs compared to conventional dosing regimen with follitropin alfa.1\u2021\u00a7 Evidence shows that beyond 15 eggs there is no additional benefit, in terms of live birth rate, in the number of eggs produced through OS in a fresh cycle.<span class=\"s2\"><sup><a href=\"#note6\">6<\/a>,<a href=\"#note7\">7<\/a><\/sup><\/span><\/p>\n[\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;]\n<h3 style=\"color: #0088ce;\">About Rekovelle (follitropin delta)<\/h3>\n<p align=\"justify\">Rekovelle is a human recombinant follicle stimulating hormone (rFSH) with an approved dosing algorithm designed for predictable ovarian response.<a href=\"#note8\"><sup>8<\/sup><\/a>\u00a0It is the first rFSH derived from a human cell line (PER.C6<sup>\u00ae<\/sup>\u00a0cell line). Rekovelle is structurally and biochemically distinct from other existing rFSH gonadotrophins.<sup><a href=\"#note8\">8<\/a>,<a href=\"#note9\">9<\/a><\/sup>\u00a0Rekovelle is approved for use in ovarian stimulation (OS) for induction of the development of multiple follicles in women undergoing assisted reproductive technologies (ART), such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI).<a href=\"#note8\"><sup>8<\/sup><\/a>\u00a0The individualised dosing of Rekovelle is determined using an approved algorithm, based on a woman\u2019s anti-M\u00fcllerian hormone (AMH) level and body weight.<sup><a href=\"#note1\">1<\/a>,<a href=\"#note8\">8<\/a>,<a href=\"#note10\">10<\/a><\/sup>\u00a0AMH is a biomarker used to assess ovarian reserve and can help predict ovarian response.<a href=\"#note11\"><sup>11<\/sup><\/a>\u00a0AMH will be measured with a companion diagnostic, the Elecsys<sup>\u00ae<\/sup>\u00a0AMH Plus immunoassay from F. Hoffmann-La Roche Ltd (Roche).<sup><a href=\"#note12\">12<\/a>,<a href=\"#note13\">13<\/a><\/sup><\/p>\n<p align=\"justify\">As of 15 June 2018, Rekovelle was approved in 37 countries and available in 17 countries worldwide.<\/p>\n<h3 style=\"color: #0088ce;\">About the ESTHER trials<\/h3>\n<p>The ESTHER trials (<strong>E<\/strong>vidence-based <strong>S<\/strong>timulation <strong>T<\/strong>rial with <strong>H<\/strong>uman recombinant FSH in <strong>E<\/strong>urope and <strong>R<\/strong>est of World) were randomised, assessor-blind, controlled, multicentre Phase 3 trials involving patients in 11 countries and over 2,000 cycles of OS.<sup><a href=\"#note1\">1<\/a>,<a href=\"#note14\">14<\/a><\/sup><\/p>\n<p>ESTHER-1 was a trial of 1,326 patients in 11 countries undergoing their first ART cycle. Patients were randomised 1:1 to receive treatment with individualised Rekovelle, a fixed daily dose based on serum AMH levels5 and body weight, or conventional follitropin alfa dosing.<sup><a href=\"#note1\">1<\/a><\/sup>\u2021 The co-primary endpoints of ongoing pregnancy rates and ongoing implantation rates were met, demonstrating comparable efficacy of Rekovelle to conventional treatment.<sup><a href=\"#note1\">1<\/a><\/sup> Rekovelle\u2019s individualised dosing regimen aims to obtain an ovarian response associated with a favourable safety\/efficacy profile, i.e. aims to achieve an adequate number of eggs and reduce interventions to prevent ovarian hyperstimulation syndrome.<sup><a href=\"#note8\">8<\/a><\/sup><\/p>\n<p>ESTHER-2 evaluated the immunogenicity of Rekovelle in a subset of ESTHER-1 patients undergoing repeated cycles of OS for ART. Data demonstrated no increased immunogenicity risk with Rekovelle after exposure in repeated cycles.<sup><a href=\"#note8\">8<\/a>,<a href=\"#note14\">14<\/a><\/sup><\/p>\n<h3 style=\"color: #0088ce;\">About Ferring Pharmaceuticals<\/h3>\n<p class=\"p1\">Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women\u2019s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.<\/p>\n<p class=\"p1\">Learn more at\u00a0<a href=\"https:\/\/www.ferring.com\/\">www.ferring.com<\/a>, or connect with us on <a href=\"https:\/\/twitter.com\/ferring\">Twitter<\/a>,\u00a0<a href=\"https:\/\/www.facebook.com\/ferringpharmaceuticals\/\">Facebook<\/a>,\u00a0<a href=\"https:\/\/www.instagram.com\/ferringpharmaceuticals\/\">Instagram<\/a>,\u00a0<a href=\"https:\/\/www.linkedin.com\/company\/ferring-pharmaceuticals\/\">LinkedIn<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.youtube.com\/channel\/UC6Ss0Uwv54xTGmM_EDEzQPA\">YouTube<\/a>.<\/p>\n<h3 style=\"color: #0088ce;\">About the Elecsys\u00ae\u00a0AMH Plus immunoassay from Roche<\/h3>\n<p>he Elecsys<sup>\u00ae<\/sup> AMH Plus immunoassay from Roche has been shown to provide a precise, reliable and robust measurement of AMH levels.<sup><a href=\"#note12\">12<\/a><\/sup><sup>,<a href=\"#note13\">13<\/a>,<a href=\"#note15\">15<\/a>,<a href=\"#note16\">16<\/a>,<a href=\"#note17\">17<\/a>,<a href=\"#note18\">18<\/a> <\/sup>This fully automated Elecsys<sup>\u00ae<\/sup>\u00a0AMH Plus immunoassay, run on the\u00a0<strong>cobas<sup>\u00ae<\/sup>\u00a0e<\/strong>\u00a0and Elecsys<sup>\u00ae<\/sup>\u00a0immunoassay analysers, determines AMH levels in 18 minutes, making it appropriate for routine clinical use. The Elecsys<sup>\u00ae<\/sup> AMH Plus immunoassay is intended to be used for assessment of ovarian reserve, prediction of response to OS and establishment of the individual daily dose of Ferring follitropin delta in combination with body weight in OS for the development of multiple follicles in women undergoing an assisted reproductive technology programme.<sup><a href=\"#note8\">8<\/a><\/sup><sup>,<a href=\"#note12\">12<\/a>,<a href=\"#note15\">15<\/a>,<a href=\"#note17\">17<\/a>,<a href=\"#note18\">18<\/a><\/sup><\/p>\n[\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;]\n<h3 style=\"color: #0088ce;\">Footnotes<\/h3>\n<p><sup><strong>*<\/strong>\u00a0<\/sup>A sub-analysis of the ESTHER-1 study population including 1,326 women (aged 18-40 years). Serum AMH was measured at a random day at screening and at cycle day 2-3 prior to stimulation using the Elecsys<sup>\u00ae<\/sup>\u00a0AMH Plus immunoassay (Roche). Limitations: A centralised AMH measuring laboratory was used which may give rise to reduced AMH variability. AMH measurements were compared with samples taken within 3 months prior to ovarian stimulation, longer time intervals may have shown different variability due to the age-related decline in AMH.<\/p>\n<p><sup><strong>\u2020<\/strong>\u00a0<\/sup>GONAL-f<sup>\u00ae<\/sup>, registered trademark of Merck KGaA, Darmstadt, Germany.<\/p>\n<p><sup><strong>\u2021<\/strong>\u00a0<\/sup>Conventional dosing of follitropin alfa is 150 IU\/d for 5 days, with potential subsequent dose adjustments at a maximum of 450 IU\/d.<sup>1<\/sup><\/p>\n<p><sup><strong>\u00a7<\/strong>\u00a0<\/sup>ESTHER-1 was neither designed nor powered to assess results based on secondary endpoints. Predefined secondary endpoints are used as a measurement to yield supportive evidence to evaluate additional effects relevant to informing the Rekovelle individualised dosing regimen. No confirmatory conclusions can be derived.<\/p>\n<p><sup><strong>**<\/strong>\u00a0<\/sup>AMH is measured by a companion diagnostic, the Elecsys<sup>\u00ae<\/sup>\u00a0AMH Plus immunoassay from F. Hoffmann-La Roche Ltd (Roche).<\/p>\n<p>&nbsp;<\/p>\n<p>&#8211; ENDS &#8211;<\/p>\n[\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;]\n<h3 style=\"color: #0088ce;\">For more information, please contact:<\/h3>\n<p><strong>Bhavin Vaid<br \/>\n<\/strong><em>Head of Corporate Communications<br \/>\n<\/em>+41 58 301 09 52 (direct)<br \/>\n+41 79 191 06 32 (mobile)<br \/>\n<span class=\"antispam\"><a href=\"mailto:bhavin.vaid@ferring.com\">bhavin.vaid@ferring.com<\/a><\/span><\/p>\n<p><strong>Lindsey Rodger<br \/>\n<\/strong><em>Senior Manager, Corporate Communications<br \/>\n<\/em>+41 58 451 40 23 (direct)<br \/>\n+41 79 191 04 86 (mobile)<br \/>\n<span class=\"antispam\"><a href=\"mailto:lindsey.rodger@ferring.com\">lindsey.rodger@ferring.com<\/a><\/span><\/p>\n[\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;]\n<h3 style=\"color: #0088ce;\">References<\/h3>\n<ol>\n<li id=\"note1\">Nyboe Andersen A, Nelson SM, Fauser BC, et al. Individualised versus conventional ovarian stimulation for an in vitro fertilization: a multicenter, randomized, controlled assessor-blinded, phase 3 noninferiority trial. Fertil Steril. 2017 02 [cited 2018 Jun 14];107(2):387-396.<\/li>\n<li id=\"note2\">Nelson SM, Larsson P, Mannaerts B, et al. AMH variability and its implications for the number of oocytes retrieved following individualized dosing with follitropin delta [abstract]: 34<span class=\"s1\">th<\/span> Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE); 2018; Barcelona, Spain. Abstract no P-651.<\/li>\n<li id=\"note3\">Fauser BC, Diedrich K, Devroey P. Evian Annual Reproduction Workshop Group 2007. Hum Reprod Update; 2008 02 [cited 2018 Jun 14];14:1\u201314.<\/li>\n<li id=\"note4\">La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update. 2014 01 [cited 2018 Jun 14;20:124\u201340.<\/li>\n<li id=\"note5\">Steward RG, Lan L, Shah AA, et al. Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles. Fertil Steril. 2014 04 [cited 2018 Jun 14];101:967\u2013973.<\/li>\n<li id=\"note6\">Drakopoulos P, Blockeel C, Stoop D, et al. Conventional ovarian stimulation and single embryo transfer for IVF\/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos? Hum Reprod. 2016 02 [cited 2018 Jun 14];31(2):370-376.<\/li>\n<li id=\"note7\">Ji J, Liu Y, Hong Tong X, et al. The optimum number of oocytes in IVF treatment: an analysis of 2455 cycles in China. Hum Reprod. 2013 10 [cited 2018 Jun 14];28(10):2728-2734.<\/li>\n<li id=\"note8\">Rekovelle<span class=\"s2\">\u00ae<\/span>\u00a0Summmary of Product Characteristics. Date of publication 2016 12 [cited 2018 Jun 14]. Available from:\u00a0<a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/003994\/WC500220238.pdf\">http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/003994\/WC500220238.pdf<\/a>.<\/li>\n<li id=\"note9\">Olsson H, Sandstr\u00f6m R, Grundemar L. Different pharmacokinetic and pharmacodynamic properties of recombinant follicle stimulating hormone (rFSH) derived from a human cell line compared with rFSH from a non-human cell line. Journal of Clinical Pharmacology. 2014 11 [cited 2018 Jun 14];54(11):1299\u2013307.<\/li>\n<li id=\"note10\">Arce JC, Nyboe Andersen A, Fernandez Sanchez M, et al. Ovarian response to recombinant human follicle stimulating hormone: a randomized, anti-M\u00fcllerian hormone\u2013stratified, dose\u2013response trial in women undergoing in vitro fertilization\/intracytoplasmic sperm injection. Fertility and Sterility. 2014 12 [cited 2018 Jun 14];102(6):1633\u20131640.<\/li>\n<li id=\"note11\">La Marca A, Sighinolfi G, Radi D, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010 03 [cited 2018 Jun 14];16(2):113-130.<\/li>\n<li id=\"note12\">Deeks ED. Elecsys<span class=\"s2\">\u00ae<\/span> AMH assay: a review in anti-M\u00fcllerian hormone quantification and assessment of ovarian reserve. Molecular Diagnosis &amp; Therapy. 2015 07 [cited 2018 Jun 14];19: 245-249.<\/li>\n<li id=\"note13\">Roche Diagnostics. Elecsys<span class=\"s2\">\u00ae<\/span>\u00a0AMH (anti-M\u00fcllerian hormone): Method sheet. (2015). Date of publication 2014 [cited 2018 Jun 14]. Available from:\u00a0<a href=\"http:\/\/www.cobas.com\/content\/dam\/cobas_com\/pdf\/product\/Elecsys%20AMH\/Elecsys%20AMH%20FactSheet.pdf\">http:\/\/www.cobas.com\/content\/dam\/cobas_com\/pdf\/product\/Elecsys%20AMH\/Elecsys%20AMH%20FactSheet.pdf<\/a>.<\/li>\n<li id=\"note14\">Buur Rasmussen A, Mannaerts B, Klein BM, et al. Low immunogenicity potential of follitropin delta, a recombinant FSH preparation produced from a human cell line: Results from phase 3 trials (ESTHER-1 and ESTHER-2). Human Reproduction. 2016 07 [cited 2018 Jun 14];31:385.<\/li>\n<li id=\"note15\">Gassner D. &amp; Jung R. First fully automated immunoassay for anti-M\u00fcllerian hormone. Clinical Chemistry and Laboratory Medicine. 2014 08 [cited 2018 Jun 14];52(8):1143-1152.<\/li>\n<li id=\"note16\">Anderson RA, Anckaert E, Bosch E, et al. Prospective study into the value of the automated Elecsys<span class=\"s2\">\u00ae<\/span> Anti-M\u00fcllerian Hormone assay for the assessment of the ovarian growing follicle pool. Fertility and Sterility. 2015 04 [cited 2018 Jun 14];103(4):1074\u20131080.e4.<\/li>\n<li id=\"note17\">Nelson SM, Pastuszek E, Kloss G, et al. Two new automated, compared with two enzyme-linked immunosorbent anti-M\u00fcllerian hormone assays. Fertility and Sterility. 2015 07 [cited 2018 Jun 14];104(4):1016-1021.e6.<\/li>\n<li id=\"note18\">Hyldgaard J, Bor P, Ingerslev HJ, et al. Comparison of two different methods for measuring anti-M\u00fcllerian hormone in a clinical series. Reproductive Biology and Endocrinology. 2015 09 [cited 2018 Jun 14];13(1):107.<\/li>\n<\/ol>\n[\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;]\n","protected":false},"excerpt":{"rendered":"<p>[spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] New analysis of Rekovelle\u00ae data further supports use of AMH to personalise fertility treatment [\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] Rekovelle\u2019s unique dosing algorithm, which is based on a woman\u2019s anti-M\u00fcllerian hormone (AMH) level and body weight, is designed for predictable ovarian response New [&hellip;]<\/p>\n","protected":false},"author":2410,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[243],"tags":[],"class_list":["post-22482","post","type-post","status-publish","format-standard","hentry","category-press-release-2018"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.3 (Yoast SEO v23.3) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>New analysis of Rekovelle\u00ae data further supports use of AMH to personalise fertility treatment - Ferring Global<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ferring.com\/new-analysis-of-rekovelle-data-further-supports-use-of-amh-to-personalise-fertility-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New analysis of Rekovelle\u00ae data further supports use of AMH to personalise fertility treatment\" \/>\n<meta property=\"og:description\" content=\"[spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] New analysis of Rekovelle\u00ae data further supports use of AMH to personalise fertility treatment [\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] Rekovelle\u2019s unique dosing algorithm, which is based on a woman\u2019s anti-M\u00fcllerian hormone (AMH) level and body weight, is designed for predictable ovarian response New [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ferring.com\/new-analysis-of-rekovelle-data-further-supports-use-of-amh-to-personalise-fertility-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Ferring Global\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ferringpharmaceuticals\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-07-02T16:27:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-05-08T09:07:15+00:00\" \/>\n<meta name=\"author\" content=\"pulse\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ferring\" \/>\n<meta name=\"twitter:site\" content=\"@ferring\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"pulse\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.ferring.com\/new-analysis-of-rekovelle-data-further-supports-use-of-amh-to-personalise-fertility-treatment\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ferring.com\/new-analysis-of-rekovelle-data-further-supports-use-of-amh-to-personalise-fertility-treatment\/\"},\"author\":{\"name\":\"pulse\",\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/person\/d1f92e22aded72904a8e0a8cdc7bcd3d\"},\"headline\":\"New analysis of Rekovelle\u00ae data further supports use of AMH to personalise fertility treatment\",\"datePublished\":\"2018-07-02T16:27:36+00:00\",\"dateModified\":\"2021-05-08T09:07:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ferring.com\/new-analysis-of-rekovelle-data-further-supports-use-of-amh-to-personalise-fertility-treatment\/\"},\"wordCount\":2039,\"publisher\":{\"@id\":\"https:\/\/www.ferring.com\/#organization\"},\"articleSection\":[\"PRESS RELEASE 2018\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ferring.com\/new-analysis-of-rekovelle-data-further-supports-use-of-amh-to-personalise-fertility-treatment\/\",\"url\":\"https:\/\/www.ferring.com\/new-analysis-of-rekovelle-data-further-supports-use-of-amh-to-personalise-fertility-treatment\/\",\"name\":\"New analysis of Rekovelle\u00ae data further supports use of AMH to personalise fertility treatment - Ferring Global\",\"isPartOf\":{\"@id\":\"https:\/\/www.ferring.com\/#website\"},\"datePublished\":\"2018-07-02T16:27:36+00:00\",\"dateModified\":\"2021-05-08T09:07:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ferring.com\/new-analysis-of-rekovelle-data-further-supports-use-of-amh-to-personalise-fertility-treatment\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ferring.com\/new-analysis-of-rekovelle-data-further-supports-use-of-amh-to-personalise-fertility-treatment\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ferring.com\/new-analysis-of-rekovelle-data-further-supports-use-of-amh-to-personalise-fertility-treatment\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ferring.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New analysis of Rekovelle\u00ae data further supports use of AMH to personalise fertility treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ferring.com\/#website\",\"url\":\"https:\/\/www.ferring.com\/\",\"name\":\"Ferring Pharmaceuticals\",\"description\":\"Helping people live better lives\",\"publisher\":{\"@id\":\"https:\/\/www.ferring.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ferring.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ferring.com\/#organization\",\"name\":\"Ferring\",\"url\":\"https:\/\/www.ferring.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/d2gohj824v350l.cloudfront.net\/wp-content\/uploads\/sites\/16\/2024\/01\/12104451\/Ferring-logo-7.png\",\"contentUrl\":\"https:\/\/d2gohj824v350l.cloudfront.net\/wp-content\/uploads\/sites\/16\/2024\/01\/12104451\/Ferring-logo-7.png\",\"width\":236,\"height\":154,\"caption\":\"Ferring\"},\"image\":{\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ferringpharmaceuticals\/\",\"https:\/\/x.com\/ferring\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/person\/d1f92e22aded72904a8e0a8cdc7bcd3d\",\"name\":\"pulse\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ferring.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0cc40dcfa5383773cc16d79b62c8436d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/0cc40dcfa5383773cc16d79b62c8436d?s=96&d=mm&r=g\",\"caption\":\"pulse\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"New analysis of Rekovelle\u00ae data further supports use of AMH to personalise fertility treatment - Ferring Global","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ferring.com\/new-analysis-of-rekovelle-data-further-supports-use-of-amh-to-personalise-fertility-treatment\/","og_locale":"en_US","og_type":"article","og_title":"New analysis of Rekovelle\u00ae data further supports use of AMH to personalise fertility treatment","og_description":"[spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] New analysis of Rekovelle\u00ae data further supports use of AMH to personalise fertility treatment [\/spb_boxed_content] [spb_blank_spacer height=&#8221;30px&#8221; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] [spb_boxed_content type=&#8221;coloured&#8221; box_link_target=&#8221;_self&#8221; padding_vertical=&#8221;0&#8243; padding_horizontal=&#8221;0&#8243; width=&#8221;1\/1&#8243; el_position=&#8221;first last&#8221;] Rekovelle\u2019s unique dosing algorithm, which is based on a woman\u2019s anti-M\u00fcllerian hormone (AMH) level and body weight, is designed for predictable ovarian response New [&hellip;]","og_url":"https:\/\/www.ferring.com\/new-analysis-of-rekovelle-data-further-supports-use-of-amh-to-personalise-fertility-treatment\/","og_site_name":"Ferring Global","article_publisher":"https:\/\/www.facebook.com\/ferringpharmaceuticals\/","article_published_time":"2018-07-02T16:27:36+00:00","article_modified_time":"2021-05-08T09:07:15+00:00","author":"pulse","twitter_card":"summary_large_image","twitter_creator":"@ferring","twitter_site":"@ferring","twitter_misc":{"Written by":"pulse","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ferring.com\/new-analysis-of-rekovelle-data-further-supports-use-of-amh-to-personalise-fertility-treatment\/#article","isPartOf":{"@id":"https:\/\/www.ferring.com\/new-analysis-of-rekovelle-data-further-supports-use-of-amh-to-personalise-fertility-treatment\/"},"author":{"name":"pulse","@id":"https:\/\/www.ferring.com\/#\/schema\/person\/d1f92e22aded72904a8e0a8cdc7bcd3d"},"headline":"New analysis of Rekovelle\u00ae data further supports use of AMH to personalise fertility treatment","datePublished":"2018-07-02T16:27:36+00:00","dateModified":"2021-05-08T09:07:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ferring.com\/new-analysis-of-rekovelle-data-further-supports-use-of-amh-to-personalise-fertility-treatment\/"},"wordCount":2039,"publisher":{"@id":"https:\/\/www.ferring.com\/#organization"},"articleSection":["PRESS RELEASE 2018"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.ferring.com\/new-analysis-of-rekovelle-data-further-supports-use-of-amh-to-personalise-fertility-treatment\/","url":"https:\/\/www.ferring.com\/new-analysis-of-rekovelle-data-further-supports-use-of-amh-to-personalise-fertility-treatment\/","name":"New analysis of Rekovelle\u00ae data further supports use of AMH to personalise fertility treatment - Ferring Global","isPartOf":{"@id":"https:\/\/www.ferring.com\/#website"},"datePublished":"2018-07-02T16:27:36+00:00","dateModified":"2021-05-08T09:07:15+00:00","breadcrumb":{"@id":"https:\/\/www.ferring.com\/new-analysis-of-rekovelle-data-further-supports-use-of-amh-to-personalise-fertility-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ferring.com\/new-analysis-of-rekovelle-data-further-supports-use-of-amh-to-personalise-fertility-treatment\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ferring.com\/new-analysis-of-rekovelle-data-further-supports-use-of-amh-to-personalise-fertility-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ferring.com\/"},{"@type":"ListItem","position":2,"name":"New analysis of Rekovelle\u00ae data further supports use of AMH to personalise fertility treatment"}]},{"@type":"WebSite","@id":"https:\/\/www.ferring.com\/#website","url":"https:\/\/www.ferring.com\/","name":"Ferring Pharmaceuticals","description":"Helping people live better lives","publisher":{"@id":"https:\/\/www.ferring.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ferring.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ferring.com\/#organization","name":"Ferring","url":"https:\/\/www.ferring.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ferring.com\/#\/schema\/logo\/image\/","url":"https:\/\/d2gohj824v350l.cloudfront.net\/wp-content\/uploads\/sites\/16\/2024\/01\/12104451\/Ferring-logo-7.png","contentUrl":"https:\/\/d2gohj824v350l.cloudfront.net\/wp-content\/uploads\/sites\/16\/2024\/01\/12104451\/Ferring-logo-7.png","width":236,"height":154,"caption":"Ferring"},"image":{"@id":"https:\/\/www.ferring.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ferringpharmaceuticals\/","https:\/\/x.com\/ferring"]},{"@type":"Person","@id":"https:\/\/www.ferring.com\/#\/schema\/person\/d1f92e22aded72904a8e0a8cdc7bcd3d","name":"pulse","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ferring.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/0cc40dcfa5383773cc16d79b62c8436d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0cc40dcfa5383773cc16d79b62c8436d?s=96&d=mm&r=g","caption":"pulse"}}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/posts\/22482"}],"collection":[{"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/users\/2410"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/comments?post=22482"}],"version-history":[{"count":0,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/posts\/22482\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/media?parent=22482"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/categories?post=22482"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ferring.com\/wp-json\/wp\/v2\/tags?post=22482"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}